Welcome to SITC Cancer Immunotherapy CONNECT, the official website of the Society for Immunotherapy of Cancer (SITC). SITC CONNECT is the hub for the latest news, research and conversation related to cancer immunotherapy.
There are a variety of actions and steps new visitors to the site can take to become active. First and foremost, creating a SITC CONNECT account will get you started, but continue reading below to learn about the additional features of this website.
Whether you're a researcher, clinician, patient, advocate or caregiver, SITC CONNECT is the source and resource for you to discuss, collaborate and learn with the best and brightest in the cancer immunotherapy space.
See you in the community!
Have a question? Need some extra guidance on getting started? Read our FAQs or send an email to firstname.lastname@example.org so we can assist you.
Create a SITC CONNECT Account
Login from the button in the top right corner using the email address and password you have previously used to login to the SITC site. As part of SITC CONNECT, the society has added a free user registration process to allow nonmembers to create profiles, network with colleagues and post in the Open Forum.
Click here to create a new account.
SITC has launched its online education portal, SITC Cancer Immunotherapy connectED. SITC connectED provides educational activities regarding current advances in the cancer immunotherapy field for patients, clinicians and researchers. Users can earn continuing education credits (CME, CNE and CPE) and apply new concepts to clinical scenarios through engaging practice activities.
Also in SITC CONNECT, visit the SITC Resource Library to access the latest learning materials, read through past discussions in the Cancer Immunotherapy CONNECT Open Forum or ask your own question.
Collaborate and network with other patients, clinicians and researchers. Use the Member Directory to find colleagues, or view your networks to find other members with similar interests. You can send contact requests to other SITC CONNECT users and share private messages.
Also, learn about what communities you have access to by logging in to your account and visiting your My Communities page.
1. Visit your profile and add a photo, biographical information and make sure your information is correct. PRO TIP: You can link your profile to your LinkedIn account to transfer over your photo and information automatically.
2. View your privacy settings to ensure they meet your preferences.
3. Using the Member Directory, search for colleagues and others around the industry to connect and grow your contact list.
1. Join in on the discussion! Post a new thread or browse current discussions for topics of interest.
2. Explore the SITC Resource Library, or share your own resources with others.
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. But cytotoxic chemotherapy can also destroy actively proliferating ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita Axelrod, MD; Stephanie Bork, MSN, CRNP; Nathaniel R. Evans III, ...
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor having experience with this treatment I would be eager to hear ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com